MicroRNA and pulmonary hypertension

Advances in Experimental Medicine and Biology

Volumn 888, Issue , 2015, Pages 237-252

  Boucherat, Olivier ^a   Potus, François ^b   Bonnet, Sébastien ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Lung; MicroRNA; PAEC; PAH; PASMC; Right ventricle

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; MICRORNA; MICRORNA 124; MICRORNA 126; MICRORNA 193; MICRORNA 208; MICRORNA 210; UNCLASSIFIED DRUG;

APOPTOSIS; CELL MIGRATION; CELL PROLIFERATION; CONGENITAL HEART MALFORMATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; FIBROBLAST; HEART RIGHT VENTRICLE FAILURE; HUMAN; LUNG VASCULAR RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; BIOLOGICAL MODEL; GENETICS; HEART RIGHT VENTRICLE HYPERTROPHY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY ARTERY; VASCULAR REMODELING; VASCULAR RESISTANCE;

HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MICRORNAS; MODELS, CARDIOVASCULAR; MODELS, GENETIC; PULMONARY ARTERY; SIGNAL TRANSDUCTION; VASCULAR REMODELING; VASCULAR RESISTANCE;

EID: 84949894825     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-22671-2_12     Document Type: Chapter

References (73)

1. Badesch DB, Champion HC, Sanchez MAG, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S55-66
2. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classifi cation of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43-54
3. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfi a PR, Kawut SM, Lumens J, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol. 2013;62(25 Suppl):D22-33
4. Fowler RM, Gain KR, Gabbay E. Exercise intolerance in pulmonary arterial hypertension. Pulm Med. 2012;2012:359204
5. Hoeper MM, Barberà JA, Channick RN, Hassoun PM, Lang IM, Manes A, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S85-96
6. Tuder RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C, Michelakis E, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D4-12
7. Cottrill KA, Chan SY. Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect. Eur J Clin Invest. 2013;43(8):855-65
8. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thébaud B, Bonnet S, et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxy-gen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation. 2006;113(22):2630-41
9. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 2005;115(6):1479-91
10. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria- K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11(1):37-51
11. Kuhr FK, Smith KA, Song MY, Levitan I, Yuan JX-J. New mechanisms of pulmonary arterial hypertension: role of Ca 2+ signaling. Am J Physiol Heart Circ Physiol. 2012;302(8): H1546-62
12. Meloche J, Paulin R, Provencher S, Bonnet S. Therapeutic potential of microRNA modulation in pulmonary arterial hypertension. Curr Vasc Pharmacol. 2015;13(3):331-40
13. Zhou G, Chen T, Raj JU. MicroRNAs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2015;52(2):139-51
14. Caruso P, MacLean MR, Khanin R, McClure J, Soon E, Southgate M, et al. Dynamic changes in lung microRNA profi les during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol. 2010;30(4):716-23
15. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000;67(3):737-44
16. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26(1):81-4
17. Shintani M, Yagi H, Nakayama T, Saji T, Matsuoka R. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet. 2009;46(5):331-7
18. Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, Zadigue P, et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest. 2009;119(3):512-23
19. Teichert-Kuliszewska K, Kutryk MJB, Kuliszewski MA, Karoubi G, Courtman DW, Zucco L, et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res. 2006;98(2):209-17
20. Yang X, Long L, Reynolds PN, Morrell NW. Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells. Pulm Circ. 2011;1(1):103-10
21. Alastalo T-P, Li M, Perez Vde J, Pham D, Sawada H, Wang JK, et al. Disruption of PPARγ/β- - catenin- mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest. 2011;121(9):3735-46
22. Kim J, Kang Y, Kojima Y, Lighthouse JK, Hu X, Aldred MA, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med. 2013;19(1):74-82
23. Bertero T, Lu Y, Annis S, Hale A, Bhat B, Saggar R, et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest. 2014;124(8):3514-28
24. Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, Gardai SJ, et al. Peroxisome proliferator- activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res. 2003;92(10):1162-9
25. Takahashi H, Goto N, Kojima Y, Tsuda Y, Morio Y, Muramatsu M, et al. Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2006;290(3):L450-8
26. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3- microRNA cluster 17/92 pathway. Circ Res. 2009;104(10):1184-91
27. Kherbeck N, Tamby MC, Bussone G, Dib H, Perros F, Humbert M, et al. The role of infl ammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin Rev Allergy Immunol. 2013;44(1):31-8
28. Huber LC, Ulrich S, Leuenberger C, Gassmann M, Vogel J, von Blotzheim LG, et al. MicroRNA-125a in pulmonary hypertension: regulator of a proliferative phenotype of endothelial cells. Exp Biol Med (Maywood). 2015;pii, 1535370215579018
29. Svensson D, Gidlöf O, Turczyńska KM, Erlinge D, Albinsson S, Nilsson B-O. Inhibition of microRNA-125a promotes human endothelial cell proliferation and viability through an antiapoptotic mechanism. J Vasc Res. 2014;51(3):239-45
30. Parikh VN, Jin RC, Rabello S, Gulbahce N, White K, Hale A, et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation. 2012;125(12):1520-32
31. Drake KM, Zygmunt D, Mavrakis L, Harbor P, Wang L, Comhair SA, et al. Altered microRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8. Am J Respir Crit Care Med. 2011;184(12):1400-8
32. Yang S, Banerjee S, de Freitas A, Cui H, Xie N, Abraham E, et al. miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol. 2012;302(6):L521-9
33. White K, Dempsie Y, Caruso P, Wallace E, McDonald RA, Stevens H, et al. Endothelial apoptosis in pulmonary hypertension is controlled by a microRNA/programmed cell death 4/caspase- 3 axis. Hypertension. 2014;64(1):185-94
34. Chan SY, Zhang Y-Y, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 2009;10(4):273-84
35. Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A. 2007;104(4):1342-7
36. Ryan JJ, Archer SL. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension. Circulation. 2015;131(19):1691-702
37. Cotroneo E, Ashek A, Wang L, Wharton J, Dubois O, Bozorgi S, et al. Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat. Circ Res. 2015;116(10):1680-90
38. White K, Lu Y, Annis S, Hale AE, Chau BN, Dahlman JE, et al. Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension. EMBO Mol Med. 2015;7(6):695-713
39. Paulin R, Meloche J, Bonnet S. STAT3 signaling in pulmonary arterial hypertension. JAKSTAT. 2012;1(4):223-33
40. Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Saksouk N, et al. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation. 2011;123(11):1205-15
41. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, et al. Role for miR- 204 in human pulmonary arterial hypertension. J Exp Med. 2011;208(3):535-48
42. Courboulin A, Tremblay VL, Barrier M, Meloche J, Jacob MH, Chapolard M, et al. Krüppellike factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res. 2011;12:128
43. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A. 2007;104(27):11418-23
44. Meloche J, Pfl ieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation. 2014;129(7):786-97
45. Meloche J, Le Guen M, Potus F, et al. miR-223 reverses experimental pulmonary arterial hypertension. Am J Physiol Cell Physiol 2015;309:C363-72. doi: 10.1152/ajpcell.00149.2015
46. Xing Y, Zheng X, Li G, Liao L, Cao W, Xing H, et al. MicroRNA-30c contributes to the development of hypoxia pulmonary hypertension by inhibiting platelet-derived growth factor receptor β expression. Int J Biochem Cell Biol. 2015;64:155-66
47. Jalali S, Ramanathan GK, Parthasarathy PT, Aljubran S, Galam L, Yunus A, et al. Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. PLoS One. 2012;7(10):e46808
48. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115(10):2811-21
49. Perros F, Montani D, Dorfmüller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178(1):81-8
50. Li X, Zhang X, Leathers R, Makino A, Huang C, Parsa P, et al. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat Med. 2009;15(11):1289-97
51. Caruso P, Dempsie Y, Stevens HC, McDonald RA, Long L, Lu R, et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res. 2012;111(3):290-300
52. Sarkar J, Gou D, Turaka P, Viktorova E, Ramchandran R, Raj JU. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol. 2010;299(6):L861-71
53. Pullamsetti SS, Doebele C, Fischer A, Savai R, Kojonazarov B, Dahal BK, et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med. 2012; 185(4):409-19
54. Brock M, Samillan VJ, Trenkmann M, Schwarzwald C, Ulrich S, Gay RE, et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodeling in hypoxia-induced pulmonary hypertension. Eur Heart J. 2014;35(45):3203-11
55. Chen T, Zhou G, Zhou Q, Tang H, Ibe JCF, Cheng H, et al. Loss of microRNA-17 ∼ 92 in smooth muscle cells attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5. Am J Respir Crit Care Med. 2015;191(6):678-92
56. Mandegar M, Yuan JXJ. Role of K+ channels in pulmonary hypertension. Vascul Pharmacol. 2002;38(1):25-33
57. Li S-S, Ran Y-J, Zhang D-D, Li S-Z, Zhu D. MicroRNA-190 regulates hypoxic pulmonary vasoconstriction by targeting a voltage-gated K + channel in arterial smooth muscle cells. J Cell Biochem. 2014;115(6):1196-205
58. Pohl NM, Yamamura A, Yamamura H, Makino A, Yuan JX-J. MicroRNA 29b is upregulated in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension and inhibits K+ channel expression and function. FASEB J. 2012;26:884
59. Guo L, Qiu Z, Wei L, Yu X, Gao X, Jiang S, et al. The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-α1C. Hypertension. 2012;59(5):1006-13
60. Zhang L, Ma J, Li Y, Guo L, Ran Y, Liu S, et al. 15-Hydroxyeicosatetraenoic acid (15-HETE) protects pulmonary artery smooth muscle cells against apoptosis via HSP90. Life Sci. 2010;87(7-8):223-31
61. Ma C, Li Y, Ma J, Liu Y, Li Q, Niu S, et al. Key role of 15-lipoxygenase/15- hydroxyeicosatetraenoic acid in pulmonary vascular remodeling and vascular angiogenesis associated with hypoxic pulmonary hypertension. Hypertension. 2011;58(4):679-88
62. Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev. 2010;18(3):141-7
63. Sharma S, Umar S, Potus F, Iorga A, Wong G, Meriwether D, et al. ApoA-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation. 2014;130(9): 776-85
64. Stenmark KR, Frid MG, Yeager M, Li M, Riddle S, McKinsey T, et al. Targeting the adventitial microenvironment in pulmonary hypertension: a potential approach to therapy that considers epigenetic change. Pulm Circ. 2012;2(1):3-14
65. Wang D, Zhang H, Li M, Frid MG, Flockton AR, McKeon BA, et al. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res. 2014;114(1):67-78
66. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009;135(3):794-804
67. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008;117(13):1717-31
68. Thum T, Batkai S. MicroRNAs in right ventricular (dys)function (2013 Grover conference series). Pulm Circ. 2014;4(2):185-90
69. Paulin R, Sutendra G, Gurtu V, Dromparis P, Haromy AS, Provencher S, et al. A miR-208- Mef2 axis drives the de-compensation of right ventricular function in pulmonary hypertension. Circ Res. 2015;116(1):56-69
70. Potus F, Graydon C, Provencher S, Bonnet S. Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover conference series). Pulm Circ. 2014;4(2):175-84
71. Potus F, Malenfant S, Graydon C, Mainguy V, Tremblay E, Breuils-Bonnet S, et al. Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2014;190(3):318-28
72. Potus F, Ruffenach G, Dahou A, et al. Downregulation of miR-126 contributes to the Failing right ventricle in pulmonary arterial hypertension. circulation 2015;132:932-43. doi: 10.1161/CIRCULATIONAHA.115.016382
73. Wei C, Henderson H, Spradley C, Li L, Kim I-K, Kumar S, et al. Circulating miRNAs as potential marker for pulmonary hypertension. PLoS One. 2013;8(5), e64396